-

KBRA Releases Monthly CMBS Trend Watch

NEW YORK--(BUSINESS WIRE)--KBRA releases the February 2022 issue of CMBS Trend Watch.

This month’s Spotlight features a review of Freddie Mac K-Series defeasance, which reached a new high in 2021, while supplemental debt originations hit a multiyear low. After a pause in 2020, borrowers once again gravitated toward defeasance in 2021, which jumped 67% to its highest level ($12.1 billion) over the last 13 years, while supplemental debt fell 28% to $1.2 billion.

CMBS private label pricing volume totaled $11.5 billion in February 2022, bringing the year-to-date (YTD) issuance total to $19.3 billion. On a year-over-year (YoY) basis, volume is up 123% from 2021. We currently have visibility of up to 18 deals that could launch in March 2022, including six to eight single-borrower (SB) transactions, four conduits, one Freddie Mac K-Series, and as many as five commercial real estate collateralized loan obligation (CRE CLO) transactions.

In February, KBRA published pre-sales for six deals ($6 billion) including three conduits ($3.4 billion), one Freddie Mac K-Series ($1.2 billion), one CRE CLO ($1.1 billion) and one small balance commercial ($278.6 million). February’s surveillance activity included rating actions on 452 classes consisting of 440 affirmations, 10 downgrades, and two upgrades. There were also 17 KBRA Performance Outlook (KPO) changes: two to Outperform from Perform, six to Perform from Underperform, and nine to Underperform from Perform.

Click here to view the report.

About KBRA

KBRA is a full-service credit rating agency registered in the U.S., the EU, and the UK, and is designated to provide structured finance ratings in Canada. KBRA’s ratings can be used by investors for regulatory capital purposes in multiple jurisdictions.

Contacts

Contacts

Giselle Vuong, Associate
+1 (646) 731-2435
giselle.vuong@kbra.com

Larry Kay, Senior Director
+1 (646) 731-2452
larry.kay@kbra.com

Eric Thompson, Senior Managing Director
+1 (646) 731-2355
eric.thompson@kbra.com

Business Development Contact

Michele Patterson, Managing Director
+1 (646) 731-2397
michele.patterson@kbra.com

KBRA

Details
Headquarters: New York City, New York
CEO: Jim Nadler
Employees: 400+
Organization: PRI

Release Versions

Contacts

Contacts

Giselle Vuong, Associate
+1 (646) 731-2435
giselle.vuong@kbra.com

Larry Kay, Senior Director
+1 (646) 731-2452
larry.kay@kbra.com

Eric Thompson, Senior Managing Director
+1 (646) 731-2355
eric.thompson@kbra.com

Business Development Contact

Michele Patterson, Managing Director
+1 (646) 731-2397
michele.patterson@kbra.com

More News From KBRA

KBRA Assigns Preliminary Ratings to Sequoia Mortgage Trust 2026-INV2 (SEMT 2026-INV2)

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to 71 classes of mortgage pass-through certificates from Sequoia Mortgage Trust 2026-INV2 (SEMT 2026-INV2). The transaction consists of 1,118 investment property mortgages with an aggregate principal balance of $438.4 million as of the March 1, 2026 cut-off date. The collateral is characterized by a weighted average (WA) original credit score of 770 and moderate borrower equity, with a WA original LTV and WA original CLTV of 73.2%. KBR...

KBRA Assigns Preliminary Ratings to Research-Driven Pagaya Motor Asset Trust 2026-R1 and Research-Driven Pagaya Motor Trust 2026-R1

NEW YORK--(BUSINESS WIRE)--KBRA assigns preliminary ratings to six classes of notes issued by Research-Driven Pagaya Motor Asset Trust 2026-R1 and Research-Driven Pagaya Motor Trust 2026-R1 (collectively “RPM 2026-R1”), an auto loan ABS transaction. RPM 2026-R1 has initial credit enhancement levels of 35.69% for the Class A notes to 2.65% for the Class E-2 notes. Credit enhancement is comprised of overcollateralization, subordination of junior note classes (except for the Class E-2 notes), a ca...

KBRA Releases Research – What’s up, Doc – Medical Professional Mortgages, A New Niche in RMBS?

NEW YORK--(BUSINESS WIRE)--KBRA releases research assessing the characteristics of medical professional mortgage (MPM) loans, with a focus on their potential role as a niche collateral segment within the prime private label residential mortgage-backed securities (RMBS) market. MPMs, often called physician or doctor loans, are specialized prime mortgage programs designed for medical professionals whose early-career financial profiles often include high student debt, limited savings, and reliance...
Back to Newsroom